Domestic HPV vaccine price and economic returns for cervical cancer prevention in China: a cost-effectiveness analysis

Coinciding with the release of the first Chinese domestic human papillomavirus (HPV) vaccine Cecolin in 2019, and the substantial advancements in cervical cancer screening technology, we aimed to evaluate the cost-effectiveness of the combined strategies of cervical cancer screening programmes and u...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	The Lancet global health 2020-10, Vol.8 (10), p.e1335-e1344
Hauptverfasser:	Zou, Zhuoru, Fairley, Christopher K, Ong, Jason J, Hocking, Jane, Canfell, Karen, Ma, Xiaomeng, Chow, Eric P F, Xu, Xianglong, Zhang, Lei, Zhuang, Guihua
Format:	Artikel
Sprache:	eng
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!